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the more severe histologic subtypes of focal prolifera-
tive and sclerosing disease has reduced O-linked sialic
acid and galactosylation than samples from normal con-
trols, and that all groups of IgAN patients have increased
exposure of N-acetylgalactosamine residues in their IgA1
compared with normal controls. This work is consistent
with previous work that also found decreased sialation
in IgAN patients (see e.g., [2] and others therein). The
decreased sialation may be fundamental in the patho-
genesis of IgAN as desialation may further expose IgA1
to degalactosylation. Such aberrantly glycosalted IgA1
may be important in the pathogenesis of IgAN because
it may be deposited in the mesangium. Whether funda-
mental to the pathogenesis or not, we just want to note
that desialation may be a useful point at which to inter-
vene for therapy for IgAN. It may be possible to screen
for and design medicinals that specifically block the de-
sialation of IgA1 without unacceptable side effects. We
further note that there is at least a small possibility that
a useful sialation inhibitor not only already exists, but
is also approved for use worldwide. Indeed, neuraminic
acid is a synonym for sialic acid. Two neuraminidase
inhibitors—oseltamivir and zanamivir—are currently li-
censed and in use worldwide for treatment and imme-
diate prophylaxis for influenza virus infection [3]. While
designed to work against the viral neuraminidase, there is
at least some evidence that these medicines are also active
against a mammalian neuraminidase [4]. Neuraminidase
inhibitors—oseltamivir and zanamivir or others—would
be a much needed addition to the treatment armamen-
tarium for IgAN and are worthy of further consideration
and potential study.
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Thrombocytopenia induced by
nicotinamide in hemodialysis
patients
To the Editor: Recently, Takahashi [1] proposed in
an article in Kidney International the prescription of
nicotinamide in order to control phosphorus level in
hemodialysis patients. Nicotinamide is a circulating form
of nicotinic acid. It was suggested that nicotinamide is
probably an effective inhibitor of phosphorus absorp-
tion in the intestine. Serum phosphorus level decreased
in the study in 65 hemodialysis patients from 2.23 ±
0.48 mmol/L to 1.74 ± 0.42 mmol/L after 12 weeks
of treatment. The authors concluded that nicotinamide
may provide an alternative for controlling hyperphos-
phatemia in hemodialysis patients.
In our dialysis unit, where we treat 100 patients, the
control of phosphoremia is essentially obtained by diet
and prescription of sevelamer [2]. Mean phosphorus level
during the last 6 months was 1.77 ± 0.36 mmol/L. Nev-
ertheless, some patients did not reach this level. We
prescribed nicotinamide in 6 of them at a dosage of
1000 mg/day. Because a transitory decline in platelet
count was described in 1 out 65 patients in the Japanese
study, we controlled the platelet count every 2 weeks.
In 1 patient the platelet count remained stable, but in 5
of them we observed a dramatic decrease in the platelet
count within 3 months of prescription.
Data are expressed as mean ± standart deviation in lL,
and a P value of less than 0.05 was considered statistically
significant. The mean platelet count 3 months before the
prescription of nicotinamide was 188,000 ± 17,000. The
mean platelet count during the 3 months of prescription
was 122,000 ± 41,000 (P < 0.001). Ten days after discon-
tinuation of the drug the mean platelet count increased to
150,000 ± 9100 (P < 0.01). For each patient, the throm-
bocytopenia was significant (P < 0.001). We looked at
the overall prescriptions of our 6 patients: the only one in
common was the prescription of sevelamer, which is not
described as inducing a thrombocytopenia. Nicotinamide
has been given over the past 40 years at high doses for a
variety of therapeutic applications [3]. Nicotinic acid and
its derivatives were seldom reported to induce thrombo-
cytopenia [4, 5]. The mechanism of this side effect has
not been completely elucidated to date: thrombocytope-
nia may result from decreased levels of thyroxin-binding
globulin induced by nicotinic acid or one of its deriva-
tives. We suggest to control very carefully the prescrip-
tion of nicotinamide in patients undergoing hemodialysis,
and probably to insist more on diet prescription than on
drugs to control hyperphosphatemia.
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Muscle IGF-I levels in
hemodialysis patients
To the Editor: We read with great interest Wang et al’s
paper [1] describing reduced skeletal muscle mRNA
levels for insulin-like growth factor (IGF)-IEa, IGF-II,
and the IGF type 1 receptor in hemodialysis (HD) pa-
tients. While the low levels of IGF-IEa mRNA relative
to healthy controls is anticipated, the elevated muscle
IGF-I protein level (mIGF-I) reported is at odds with
the diminished levels, relative to healthy controls previ-
ously reported in our HD patients [2] and animal mod-
els of chronic renal failure (CRF) (e.g. [3]). An obvious
difference between these studies is that in contrast to
our patients and CRF rats, the HD patients recruited by
Wang et al were not muscle wasted. This supports our
contention that mIGF-I may play an important role in
muscle atrophy in CRF populations.
Notwithstanding species and methodologic differ-
ences, we were also surprised by the huge disparity in
mean mIGF-I levels reported by this group for HD pa-
tients and CRF rats [1, 3]. Assuming a protein content of
15.5% in wet skeletal muscle for nonobese humans [4],
the 131 and 100 ng IGF-I/mg wet muscle values reported
by Wang et al convert to 845 and 645 ng IGF-I/mg muscle
protein for HD patients and controls, respectively. These
values are 1 to 2×105 greater than those reported by Ding
et al (0.0042 and 0.0069 ng/mg muscle protein for CRF
and control rats, respectively). Are the units correctly
stated in these papers? Additionally, the serum IGF val-
ues in Wang et al’s paper need to be reported as ng/mL,
not lg/mL, to be correct.
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Anti-proteinase 3 antibody
binding to neutrophils as
demonstrated by confocal
microscopy
To the Editor: We read with great interest the article
by Van Rossum et al [1] and wish to provide supplemen-
tary microscopic evidence of binding of anti-neutrophil
cytoplasm antibodies (ANCA) to a subset of neutrophils.
Following the report by Abdel-Salam et al [2] of a fail-
ure of ANCA to bind to neutrophils, we investigated
binding of anti-PR3 antibody positive serum from pa-
tients with systemic vasculitis to human neutrophils using
indirect immunofluorescence and confocal microscopy,
as detailed in Figure 1. The priming and staining proce-
dure was virtually identical to that used by Van Rossum
et al, with the addition of an incubation step with
the neutrophil marker CD16. Our results support their
findings, with membrane staining of a fraction of neu-
trophils incubated with anti-PR3–positive serum. Thus,
the hypothesis that ANCA binding in vivo results in
dysregulated degranulation of neutrophils [3] remains
viable.
